144 related articles for article (PubMed ID: 26199394)
61. Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol.
Clark E; Morton M; Sharma S; Fisher H; Howel D; Walker J; Wood R; Hancock H; Maier R; Marshall J; Bahl A; Crabb S; Jain S; Pedley I; Jones R; Staffurth J; Heer R
BMJ Open; 2019 Dec; 9(12):e034708. PubMed ID: 31857319
[TBL] [Abstract][Full Text] [Related]
62. mRNA expressions of androgen receptor and its variants in matched hormone-sensitive and castration-resistant prostate cancer.
Park HK; Lim SD; Kwon GY
Scand J Urol; 2019 Dec; 53(6):365-371. PubMed ID: 31809622
[No Abstract] [Full Text] [Related]
63. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
64. Prostate cancer: predicting resistance-AR-V7 is a potential biomarker.
Stone L
Nat Rev Urol; 2014 Nov; 11(11):606. PubMed ID: 25266571
[No Abstract] [Full Text] [Related]
65. Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression.
Pimenta R; Malulf FC; Romão P; Caetano GVB; da Silva KS; Ghazarian V; Dos Santos GA; Guimarães V; Silva IA; de Camargo JA; Recuero S; Melão BVLA; Antunes AA; Srougi M; Nahas W; Leite KRM; Reis ST
J Cancer Res Clin Oncol; 2024 Feb; 150(2):70. PubMed ID: 38305916
[TBL] [Abstract][Full Text] [Related]
66. Androgen receptor variation affects prostate cancer progression and drug resistance.
McCrea E; Sissung TM; Price DK; Chau CH; Figg WD
Pharmacol Res; 2016 Dec; 114():152-162. PubMed ID: 27725309
[TBL] [Abstract][Full Text] [Related]
67. Estrogen-Mediated Activation of H875Y Androgen Receptor Mutation in a Prostate Cancer Patient.
Vasudevamurthy AK; Ledet E; Garvey C; Lewis BE; Sartor O
Clin Genitourin Cancer; 2017 Feb; 15(1):e111-e113. PubMed ID: 27527401
[No Abstract] [Full Text] [Related]
68. Drug development. New way to target hormone receptor thwarts prostate cancer.
Kaiser J
Science; 2009 Apr; 324(5924):165. PubMed ID: 19359556
[No Abstract] [Full Text] [Related]
69. Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.
Nakata W; Yamamichi G; Tsujimura G; Tsujimoto Y; Nin M; Tsujihata M
Int J Urol; 2020 Jan; 27(1):87-89. PubMed ID: 31602723
[No Abstract] [Full Text] [Related]
70. Clinical decision-making with AR-V7.
Thoma C
Nat Rev Urol; 2019 Dec; 16(12):694. PubMed ID: 31690843
[No Abstract] [Full Text] [Related]
71. Anti-androgen monotherapy for metastatic prostate cancer.
Attard G
Lancet Oncol; 2014 May; 15(6):543-4. PubMed ID: 24739898
[No Abstract] [Full Text] [Related]
72. Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen?
Jun T; Oh WK
JAMA Oncol; 2022 Jul; 8(7):972-974. PubMed ID: 35551363
[No Abstract] [Full Text] [Related]
73. Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells.
Cummings J; Sloane R; Morris K; Zhou C; Lancashire M; Moore D; Elliot T; Clarke N; Dive C
BMC Cancer; 2014 Mar; 14():226. PubMed ID: 24674711
[TBL] [Abstract][Full Text] [Related]
74. Design and synthesis of 4-acetoxypentanamide derivatives of spliceostatin A and their biological evaluation towards prostate cancer treatment.
Hirabayashi S; Tsuyuguchi Y; Li Y; Ohta N; Yoshikawa Y; Lin B; Fumimoto M; Nunomura K; Suzuki T; Haruta J; Nimura K; Arisawa M
Bioorg Med Chem Lett; 2023 Jul; 91():129333. PubMed ID: 37207846
[TBL] [Abstract][Full Text] [Related]
75. UT-34: a promising new AR degrader.
Stone L
Nat Rev Urol; 2019 Nov; 16(11):640. PubMed ID: 31578494
[No Abstract] [Full Text] [Related]
76. Circulating tumor cells positivity provides an early detection of recurrence of pancreatic cancer.
Wang HT; Bai LY; Wang YT; Lin HJ; Yang HR; Hsueh PR; Cho DY
J Formos Med Assoc; 2023 Jul; 122(7):653-655. PubMed ID: 36775680
[No Abstract] [Full Text] [Related]
77. [Register for new drugs in cancer care provides a picture of how the drugs are used in the daily clinical practice].
Henriksson R; Falkenius J; Norin S; Öhman D; Abrahamsson M; Lindquist M; Lööv SÅ
Lakartidningen; 2017 Nov; 114():. PubMed ID: 29292905
[TBL] [Abstract][Full Text] [Related]
78. Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer.
Chakraborty G; Gupta K; Kyprianou N
Nat Commun; 2023 Feb; 14(1):567. PubMed ID: 36732329
[TBL] [Abstract][Full Text] [Related]
79. ENTPD5 splice variants: novel players in cancer?
Arruga F
Purinergic Signal; 2021 Sep; 17(3):317-318. PubMed ID: 34272651
[No Abstract] [Full Text] [Related]
80. Reply to K.S. Shohdy et al.
Traina TA; Cortes J
J Clin Oncol; 2018 Aug; 36(23):2458-2459. PubMed ID: 29847296
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
